Astellas PharmaALPMF +10.51%73 Days Payable is 187.50 as of Mar. 2026, which is 7% below its 10-year median of 201.93. GuruFocus rates ALPMF with a GF Score™ of 73/100 and a GF Value™ of $14.67 (Fairly Valued). The stock has 4 warning signs investors should review. Among 920 Drug Manufacturers companies, Astellas Pharma ranks better than 78.15% on this metric.
The historical rank and industry rank for Astellas Pharma's Days Payable or its related term are showing as below:
ALPMF'
s Days Payable Range Over the Past 10 Years
Min: 161.59 Med: 201.93 Max: 235.58
Current: 161.59
During the past 13 years, Astellas Pharma's highest Days Payable was 235.58. The lowest was 161.59. And the median was 201.93.
ALPMF's Days Payable is ranked better than 78.15% of 920
companies
in the Drug Manufacturers industry
Industry Median: 90.835
vs ALPMF: 161.59
Astellas Pharma's Days Payable
declined
from Mar. 2025 (229.04) to Mar. 2026 (187.50).
It may suggest that Astellas Pharmaaccelerated paying its suppliers.
Astellas Pharma Days Payable Related Terms
Astellas Pharma Days Payable Historical Data
* Premium members only.
The historical data trend for Astellas Pharma's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Astellas Pharma's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Astellas Pharma Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Astellas Pharma's Days Payable distribution charts can be found below:
* The bar in red indicates where Astellas Pharma's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Astellas Pharma's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Astellas Pharma (ALPMF) has a Days Payable of 187.50 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Astellas Pharma and its competitors. This is near median its historical median of 201.93. Over the past decade, Astellas Pharma's Days Payable has ranged from 161.59 to 235.58. According to the industry distribution chart, Astellas Pharma ranks #201 out of 920 companies in the Drug Manufacturers industry, placing it in the top 21.8%.
Is Astellas Pharma's Days Payable too high?
Astellas Pharma's current Days Payable of 187.50 is near median its 10-year median of 201.93. Over the past 10 years, this metric has ranged from a low of 161.59 to a high of 235.58. The Drug Manufacturers industry median Days Payable is 90.84. Astellas Pharma's value of 187.50 is 106.4% above this industry median. Based on the distribution chart, Astellas Pharma ranks #201 out of 920 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Astellas Pharma has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Astellas Pharma's Days Payable compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Astellas Pharma ranks #201 out of 920 companies for Days Payable. This places Astellas Pharma in the top 22% of its industry — outperforming the majority of peers. The industry median Days Payable is 90.84. Astellas Pharma's value of 187.50 is 106.4% above this benchmark. Historically, Astellas Pharma's own Days Payable has ranged from 161.59 to 235.58 over the past decade. While the company's 10-year median is 201.93 vs. the industry median of 90.84, Astellas Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.84, based on 920 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Astellas Pharma's current Days Payable of 187.50 is 106.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Astellas Pharma and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Astellas Pharma's current Days Payable is 187.50, which is near median its own 10-year median of 201.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Astellas Pharma stock overvalued right now?
Based on GuruFocus' analysis, Astellas Pharma (ALPMF) is currently considered Fairly Valued. The stock's GF Value™ is $14.67, compared to a current price of $14.20 — trading 3.2% below its estimated fair value. The current Days Payable is 187.50, which is near median its 10-year median of 201.93 and 106.4% above the Drug Manufacturers industry median of 90.84. Astellas Pharma's overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Astellas Pharma (ALPMF), the current Days Payable is 187.50 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Astellas Pharma (ALPMF) Overvalued in 2026?
Based on GuruFocus' analysis, Astellas Pharma stock appears to be undervalued.
The current stock price of $14.20 is trading 3.2% below its estimated GF Value™ of $14.67.
GuruFocus considers Astellas Pharma to be Fairly Valued.
Key valuation signals for ALPMF:
Days Payable: 187.50 (near median its 10-year median of 201.93)
GF Value™: $14.67 vs. price of $14.20 (3.2% below fair value)
Industry Position: 106.4% above the Drug Manufacturers median (#201 of 920)
No single metric tells the full story. See the ALPMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Astellas Pharma Inc is a specialty international pharmaceutical company. The company focuses on accelerating the discovery, development, and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.
73GF Score
Get the complete analysis for ALPMF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALPMF has been successfully added to your 
